Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=24003209
&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215
Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\24003209
.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117 Cold+Spring+Harb+Perspect+Biol
2013 ; 5
(9
): ä Nephropedia Template TP
Cold Spring Harb Perspect Biol
2013[Sep]; 5
(9
): ä PMID24003209
show ga
The endothelial cell is the essential cell type forming the inner layer of the
vasculature. Two families of receptor tyrosine kinases (RTKs) are almost
completely endothelial cell specific: the vascular endothelial growth factor
(VEGF) receptors (VEGFR1-3) and the Tie receptors (Tie1 and Tie2). Both are key
players governing the generation of blood and lymphatic vessels during embryonic
development. Because the growth of new blood and lymphatic vessels (or the lack
thereof) is a central element in many diseases, the VEGF and the Tie receptors
provide attractive therapeutic targets in various diseases. Indeed, several drugs
directed to these RTK signaling pathways are already on the market, whereas many
are in clinical trials. Here we review the VEGFR and Tie families, their
involvement in developmental and pathological angiogenesis, and the different
possibilities for targeting them to either block or enhance angiogenesis and
lymphangiogenesis.
free
free
free
